Zoledronic Acid Administration in Aggressive Castration-Resistant Prostate Cancer

DOI QR Code

Taguchi, Satoru (Department of Urology, Graduate School of Medicine, The University of Tokyo) ;
Fujimura, Tetsuya (Department of Urology, Graduate School of Medicine, The University of Tokyo) ;
Kume, Haruki (Department of Urology, Graduate School of Medicine, The University of Tokyo) ;
Homma, Yukio (Department of Urology, Graduate School of Medicine, The University of Tokyo)

Cho D, Di Blasio CJ, Rhee AC, Kattan MW (2003) Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol, 21, 282-91. https://doi.org/10.1016/S1078-1439(03)00057-7
Gnant M (2011). Zoledronic acid in breast cancer: latest findings and interpretations. Ther Adv Med Oncol, 3, 293-301. https://doi.org/10.1177/1758834011420599
Gnant M, Mlineritsch B, Stoeger H, et al (2011). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month followup from the ABCSG-12 randomised trial. Lancet Oncol, 12, 631-41. https://doi.org/10.1016/S1470-2045(11)70122-X
Kikuno N, Urakami S, Nakamura S, Shiina H, Igawa M (2007). Effect of zoledronic acid on metastatic hormonerefractory prostate cancer resistant to taxane, estramusutine, carboplatin, and dexamethasone. Int J Urol, 14, 82-4. https://doi.org/10.1111/j.1442-2042.2006.01566.x

Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10729